China Pharma Holdings, Inc.: Form 10-Q for the period ended Sep 30, 2016
Filed with the SEC on Nov 14, 2016 and accepted by EDGAR at Nov 14, 2016, 16:07 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2016-07-01 to 2016-09-30 | $3.1m | us-gaap:Revenues |
| Revenue | 9 months2016-01-01 to 2016-09-30 | $10.3m | us-gaap:Revenues |
| Cost of revenue | 3 months2016-07-01 to 2016-09-30 | $2.7m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2016-01-01 to 2016-09-30 | $8.6m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2016-07-01 to 2016-09-30 | $350.0k | us-gaap:GrossProfit |
| Gross profit | 9 months2016-01-01 to 2016-09-30 | $1.5m | us-gaap:GrossProfit |
| Research and development | 3 months2016-07-01 to 2016-09-30 | $99.1k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2016-01-01 to 2016-09-30 | $289.2k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2016-07-01 to 2016-09-30 | −$1.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2016-01-01 to 2016-09-30 | −$5.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2016-07-01 to 2016-09-30 | $213.7k | us-gaap:InterestExpense |
| Interest expense | 9 months2016-01-01 to 2016-09-30 | $699.9k | us-gaap:InterestExpense |
| Income tax | 3 months2016-07-01 to 2016-09-30 | −$20.8k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2016-01-01 to 2016-09-30 | −$65.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2016-07-01 to 2016-09-30 | −$1.7m | us-gaap:NetIncomeLoss |
| Net income | 9 months2016-01-01 to 2016-09-30 | −$5.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2016-07-01 to 2016-09-30 | −$0.04 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2016-01-01 to 2016-09-30 | −$0.13 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2016-07-01 to 2016-09-30 | −$0.04 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2016-01-01 to 2016-09-30 | −$0.13 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2016-07-01 to 2016-09-30 | 43,579,557 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2016-01-01 to 2016-09-30 | 43,579,557 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2016-01-01 to 2016-09-30 | $1.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2016-01-01 to 2016-09-30 | $86.3k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Current assets | At period end2016-09-30 | $21.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2016-09-30 | $87.4m | us-gaap:Assets |
| Current liabilities | At period end2016-09-30 | $13.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2016-09-30 | $22.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2016-09-30 | $64.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001010549-16-000787. Last ingested by Listed: Oct 30, 2026, 16:51 ET. Listed shows no prices and gives no investment advice.